OMER Stock — Omeros Corporation: Cash, EV, Pipeline

Share price

$17.87

Market cap

$1,293.6M

Cash

$132.0M

Enterprise value

$1,249.5M

Balance sheet

Cash	$132.0M
Debt	$87.9M
Net cash	$44.1M
Enterprise value	$1,249.5M
Basic shares	72.1M shares
Fully diluted shares	105.4M shares
Fully diluted market cap	$1,884.2M
Cash per share	$1.83

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading OMER daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	OMS906 study drug	Phase 2	Paroxysmal Nocturnal Hemoglobinuria	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

YARTEMLEA

Approved · Active Modality: antibody

Aliases narsoplimab-wuug

Target MASP-2

Indications

Hematopoietic stem cell transplant-associated thrombotic microangiopathy (Approved)

Status note MASP-2 antibody commercially available in the U.S. for TA-TMA in adult and pediatric patients 2+ years; EMA reexamination of the MAA for TA-TMA ongoing.

Zaltenibart

Stage not disclosed · Active

Target MASP-3

Partnerships Novo Nordisk (APLA; $240M upfront received; up to $510M development/approval milestones, up to $1.3B sales milestones; Novo Nordisk leads development)

Indications

not disclosed (Stage not disclosed)

Status note Development program transferred to Novo Nordisk under the APLA; Omeros retains milestone economics including $100M near-term milestones expected achievable.

OMS1029

Phase 1 · Active Modality: antibody

Target MASP-2

Indications

not disclosed (Phase 1)

Status note Long-acting anti-MASP-2 antibody (once-quarterly IV or SC). Phase 1 SAD/MAD completed; indication for Phase 2 program being finalized.

MASP-2 small molecule program

Discovery · Active Modality: small molecule

Target MASP-2

Indications

not disclosed (Discovery)

Status note MASP-2 small molecule program; development candidate selection expected after completion of one ongoing study (once-daily oral).

OMS527

Phase 1 · Active Modality: small molecule

Target PDE7

Partnerships NIDA ($6.24M grant awarded Apr 2023; $2.3M received)

Indications

Cocaine use disorder (Phase 1)

Status note PDE7 inhibitor program for addiction/compulsive disorders. Lead oral compound completed Phase 1; NIDA-funded preclinical interaction/toxicology studies for cocaine use disorder completed; FDA requested additional nonclinical information before clinical initiation.

OncotoX-AML

Preclinical · Active Modality: large molecule

Aliases OMS805

Indications

Acute myeloid leukemia (Preclinical)

Status note Novel proprietary large molecule designed to selectively target/kill dividing cancer cells; IND-enabling studies underway; AML is lead indication.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	OMS906 study drug
Lead indication	Paroxysmal Nocturnal Hemoglobinuria
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06298955	Phase 2	Active, not recruiting	Sponsor	OMER	—	Paroxysmal Nocturnal Hemoglobinuria	—
NCT05855083	Phase 2	Recruiting	Sponsor	OMER	—	Thrombotic Microangiopathies; Hematopoietic Stem Cell Transplantation	—
NCT06209736	Phase 2	Recruiting	Sponsor	OMER	—	C3 Glomerulopathy; Idiopathic Immune Complex-Mediated Glomerulonephritis	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Omeros Corporation on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

OMER — Omeros Corporation

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials